Inactive Instrument

BIO-TECHNE Corp Stock Nasdaq

Equities

US8783771004

Biotechnology & Medical Research

End-of-day quote Nasdaq
- USD - Intraday chart for BIO-TECHNE Corp
Sales 2024 * 1.16B Sales 2025 * 1.25B Capitalization 12.23B
Net income 2024 * 180M Net income 2025 * 228M EV / Sales 2024 * 10.7 x
Net Debt 2024 * 166M Net cash position 2025 * 85.4M EV / Sales 2025 * 9.73 x
P/E ratio 2024 *
69.4 x
P/E ratio 2025 *
55.5 x
Employees -
Yield 2024 *
0.41%
Yield 2025 *
0.41%
Free-Float 99.03%
More Fundamentals * Assessed data
Transcript : Bio-Techne Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:30 AM
Transcript : Bio-Techne Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 09:20 AM
Bio-Techne Corporation to Showcase Multiple Applications of the MauriceFlex?? System at the Annual ASMS Conference CI
Transcript : Bio-Techne Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 08:40 AM
Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration CI
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing MT
Transcript : Bio-Techne Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85 MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80 MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept MT
Baird Adjusts Bio-Techne Price Target to $81 From $73 MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged MT
More news
Managers TitleAgeSince
Chief Executive Officer 57 18-04-29
Director of Finance/CFO 53 14-03-31
Chief Operating Officer 55 Jan. 07
Members of the board TitleAgeSince
Chairman 68 02-12-31
Director/Board Member 74 89-12-31
Director/Board Member 71 17-10-25
More insiders
Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).
Related indices
More about the company